Subscribe or Manage Preferences
“Mandatory staff meeting on ICD-10, Thursday morning at 7,” the e-mail read.
Zitter Health Insights (ZHI) recently released the latest edition of its Co-Pay Offset Monitor, a publication that serves as a research tool to help identify trends in copay assistance. The group surveyed 100 rheumatologists, 100 patients who had used copay offset programs (COPs) for their medications over the previous 6 months, and 25 specialty pharmacists. The report shows that COPs have been growing at a high rate.
In just a few short months we will be in Louisville, KY, for our National Organization of Rheumatology Managers (NORM) conference, which is scheduled for September 12-13, 2014. Members of the NORM Board of Directors and various committees have spent innumerable hours throughout the year in planning and organizing the conference so it can meet our members’ expectations.
Assisting patients with copays has become a big part of medication payment programs over the last few years. Many pharmaceutical companies view this as a way to maintain market share and help consumers cope with multiple payment tiers.
You make more money than you spend. It’s the right problem to have, but it’s a problem nonetheless.
The alignment of physicians with hospitals and health systems is increasingly challenging in today’s healthcare climate. In the past, many physicians viewed hospitals as potential partners with endless channels of money by which they could augment their previous private practice incomes.
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease that affects at least 1.3 million adults in the United States.1 Symptoms include pain, stiffness, swelling, and limited motion and function of many joints, particularly the small joints in the hands and feet.
The challenges involved with the start of implementation of the Affordable Care Act (ACA)’s insurance exchange program are evident in the responses to an April 2014 survey by the Medical Group Management Association (MGMA).
A recent retrospective study of 114 patients with hypogonadism has led to the conclusion that men with this condition should be screened with dual-energy x-ray absorptiometry (DEXA) for low bone mineral density (BMD).

Results 1 - 9 of 9
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management

Search